HOPE study impact on ACE inhibitors use

Annals of Pharmacotherapy

Volumn 37, Issue 5, 2003, Pages 640-645

  Hemels, Michiel E H ^a,d   Bennett, Heather A ^b   Bonari, Lori ^b   Han, Donald ^b   Traverso, Maria L ^c   Einarson, Thomas R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

ACE inhibitors; Canada; Drug utilization; HOPE trial; Ramipril

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; DRUG COST; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CANADA; CAPTOPRIL; CARDIOVASCULAR DISEASES; DRUG UTILIZATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; RAMIPRIL; TIME FACTORS;

EID: 0037407476     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C339     Document Type: Article

References (29)

1. Feldman RD, Campbell NR, Larochelle P, Bolli P, Burgess ED, Carruthers SG, et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Canadian Recommendations for the Management of Hypertension. CMAJ 1999;161(suppl 12):S1-17.
2. Waugh WJ. Factors to consider in selecting angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 2000;57(suppl):S26-30.
3. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR. Emerging role of angiotensin-converting-enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibitors on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
5. Compendium of pharmaceuticals and specialties. 36th ed. Ottawa, Canada: Canadian Pharmacists Association, 2001.
6. Statistics Canada. Canada at a glance 2002. www.hc-sc.gc.ca (accessed 2002 Apr 25).
7. Heart and Stroke Foundation of Canada. The changing face of heart disease and stroke in Canada 2000. www.hc-sc.gc.ca (accessed 2002 Apr 25).
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
9. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
10. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.
11. Patented Medicine Prices Review Board. Anatomical therapeutic chemical (ATC) classification system for human medicines (Canada). Ottawa, Canada: Patented Medicine Prices Review Board, 1995.
12. IMS Health Canada. Academic reference manual 2001. Mississauga, Canada: IMS Health, 2001.
13. IMS Health Canada. Canadian Pharmaceutical Market. Drug store and hospital purchase audit (CD&H). Mississauga, Canada: IMS Health, 2002.
14. MS Health Canada. Canadian CompuScript (CompuScript). Mississauga, Canada: IMS Health, 2002.
15. IMS Health Canada. Uniform system of classification or therapeutic class (USC). Mississauga, Canada: IMS Health, 2001.
16. Statistics Canada, Canadian statistics. Consumer price index, healthcare. www.statcan.ca (accessed 2002 Apr 25).
17. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
18. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
19. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
20. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.
21. Bart BA, Gattis WA, Diem SJ. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997;79:1118-20.
22. Bown Luzier A, Forest A, Adelman M. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998;82:465-9.
23. Clark A, Coats AJS. Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. BMJ 1995;310:973-4.
24. Stafford RS, Saglan D, Blumenthal D. National patterns of angiotensin converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997;157:2460-4.
25. Teo K, Montague T, Ackman M. Mortality risk in patients with congestive heart failure: the relative importance of age, sex and medical therapy. Arch Intern Med 1996;156:1669-73.
26. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. Arch Intem Med 1997;157:1103-8.
27. Report of the Standing Senate Committee on Social Affairs, Science and Technology on the state of the health care system in Canada. The health of Canadians - the federal role. Volume two: current trends and future challenges. Ottawa, Canada: January 2002. www.healthcarecommission.ca. (accessed 2002 May 8).
28. Drug expenditures in Canada 1985-2000. Ottawa, Canada: Canadian Institute for Health Information, 2001.
29. Dubois RW, Chawla AJ, Neslusan CA. Explaining drug spending trends: does perception match reality? Health Aff 2000;19:231-9.